Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncolytics Biotech, Inc. (ONCY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent for pancreatic, breast, and gastrointestinal cancers. Its filings help investors understand how the company describes its programs, capital plans, and corporate structure.
Oncolytics files a range of documents, including Forms 6-K and 8-K that furnish or report material events and press releases. Recent 6-K reports have included information on the formation and expansion of a Gastrointestinal Tumor Scientific Advisory Board, progress toward pivotal and registration-directed studies in pancreatic, colorectal, and anal cancers, and details of an at-the-market sales agreement used to fund pelareorep’s clinical development and general corporate purposes. A Form 8-K has reported leadership appointments in strategy, operations, and biostatistics intended to support late-stage clinical execution.
Filings also describe corporate and jurisdictional changes, such as the proposed domestication from Alberta, Canada, to the State of Nevada in the United States, the company’s transition from foreign private issuer status to domestic issuer status, and related proxy and registration materials. These documents outline the rationale for reducing regulatory complexity, aligning domicile with U.S.-based operations and shareholders, and improving access to U.S. capital markets.
On Stock Titan, investors can review these SEC filings alongside AI-powered summaries that highlight key points, such as clinical trial plans, financing arrangements, and governance changes. Real-time updates from EDGAR, combined with AI explanations of complex documents like registration statements and current reports, help users quickly understand how ONCY’s regulatory disclosures relate to its immuno-oncology strategy and pelareorep development programs.
Oncolytics Biotech Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell shares of common stock with an aggregate offering price of up to $75.0 million through an at-the-market program.
Sales will be made from time to time under the company’s effective Form S-3 shelf registration, with Jefferies acting as agent or principal and earning a commission of up to 3.0% of gross proceeds. The company plans to use any net cash raised to fund clinical development of pelareorep, related research and development, operating costs, working capital and general corporate purposes.
Oncolytics Biotech Inc. has filed a prospectus supplement to offer up to $75,000,000 of common stock through an at-the-market sales agreement with Jefferies LLC. Sales may occur from time to time at market prices; Jefferies may act as agent or principal and may earn commissions up to 3.0%.
The company states net proceeds will be used to fund clinical development of pelareorep, R&D, operating costs and general corporate purposes. The prospectus cites 108,021,271 shares outstanding as of December 31, 2025 and presents a pro forma example (sale of 78,125,000 shares at $0.96) producing up to 186,146,271 shares outstanding.
Oncolytics Biotech Inc. has scheduled a Type C meeting with the U.S. FDA on April 16, 2026 to discuss a potential single-arm registrational study of pelareorep plus a checkpoint inhibitor in second-line and later squamous cell anal carcinoma (SCAC).
The company plans to propose a pivotal trial enrolling approximately 60–70 patients, using objective response rate as the primary endpoint to support potential full approval. In Cohort 4 of the GOBLET study, pelareorep plus a checkpoint inhibitor achieved an approximately 30% objective response rate and a median duration of response of 17 months in late-line SCAC, compared with real-world response rates of about 10–14% and a median duration of response of roughly 9.5 months.
Oncolytics highlights SCAC as a rare cancer with limited second-line and later treatment options and notes external estimates of about 54,000 anal cancer cases globally each year, with the anal cancer market projected to reach $2.3 billion by 2035.
Oncolytics Biotech Inc. has completed a two-step redomestication, moving its jurisdiction of incorporation from Alberta to British Columbia and then, on March 31, 2026, to Nevada, while keeping its name and Nasdaq listing under the ticker ONCY.
Each outstanding share automatically became one share of Nevada common stock with a $0.001 par value, and a new CUSIP (68237V 103) and ISIN (US68237V1035) now apply. The company adopted new Nevada Articles of Incorporation and Bylaws, entered into indemnification and advancement agreements with directors and executive officers, and designated Nevada and U.S. federal courts as exclusive forums for certain claims.
In connection with the move, the board approved a new 2026 Incentive Award Plan with 6,500,000 shares available plus additional shares from prior plans and an annual increase formula through 2036, while closing prior equity plans to new awards. New risk factors highlight that Nevada law and the governing documents may reduce stockholder rights and make corporate disputes and changes in control more difficult.
Oncolytics Biotech Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities, including common stock, preferred stock, warrants, purchase contracts and units. The filing also re-registers $139.0 million of unsold securities from a prior Form F-3 under Rule 415(a)(6). The prospectus is a base shelf: specific terms, amounts and prices for each offering will be provided in future prospectus supplements.
Oncolytics Biotech Inc. files its annual report as a clinical-stage biotech focused on developing pelareorep, an intravenously delivered oncolytic virus immunotherapy for multiple cancers, especially gastrointestinal and breast tumors. The company has no approved products and does not expect significant revenue until pelareorep is commercialized.
Management discloses substantial doubt about its ability to continue as a going concern over the next 12 months, citing recurring losses and limited cash, and states that continued operations depend on raising additional capital. The filing details extensive clinical data, patent protection into at least 2031 with new applications potentially extending into the 2040s, and outlines intense competition and significant regulatory, financing, and execution risks, including an ongoing corporate domestication process from Canada to Nevada.
Oncolytics Biotech Inc. has completed the first step of its planned two-step redomestication by changing its jurisdiction of incorporation from Alberta to British Columbia, Canada, via a statutory continuance under the ABCA and BCBCA. Shareholders approved the continuance and subsequent U.S. domestication at a special meeting held on January 15, 2026.
All outstanding common shares remain outstanding as common shares of the British Columbia entity, with no change to the company’s name or Nasdaq ticker, which continues as ONCY. The current CUSIP (682310875) and ISIN (CA6823108759) remain in place until the expected second step, when the company plans to domesticate to Nevada on March 31, 2026. Effective April 1, 2026, the CUSIP is expected to change to 68237V103 and the ISIN to US68237V1035 while the stock continues trading on Nasdaq as common stock of a Nevada corporation.
Oncolytics Biotech Inc. reported that two new scientific abstracts featuring its investigational immunotherapy pelareorep have been accepted for presentation at the AACR 2026 Annual Meeting. The data come from the GOBLET study in metastatic pancreatic cancer and the AWARE-1 study in early-stage breast cancer.
GOBLET biomarker analyses suggest that adding pelareorep to atezolizumab and chemotherapy can shift pancreatic tumors toward a more immune-active state, with patients showing immune activation signatures experiencing longer progression-free survival and previously reported higher response rates than with chemotherapy alone. AWARE-1 data show pelareorep can drive coordinated anti-tumor immune responses and tertiary lymphoid structure formation, potentially turning immunologically “cold” breast tumors into more treatment-responsive “hot” tumors, supporting pelareorep as an immune-priming backbone for combination therapies across multiple tumor types.